APA (7th ed.) Citation

Marson, A., Burnside, G., Appleton, R., Smith, D., Leach, J. P., Sills, G., . . . collaborators, S. I. (2021). The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: An open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, 397(10282), 1363. https://doi.org/10.1016/S0140-6736(21)00247-6

Chicago Style (17th ed.) Citation

Marson, Anthony, et al. "The SANAD II Study of the Effectiveness and Cost-effectiveness of Levetiracetam, Zonisamide, or Lamotrigine for Newly Diagnosed Focal Epilepsy: An Open-label, Non-inferiority, Multicentre, Phase 4, Randomised Controlled Trial." Lancet 397, no. 10282 (2021): 1363. https://doi.org/10.1016/S0140-6736(21)00247-6.

MLA (9th ed.) Citation

Marson, Anthony, et al. "The SANAD II Study of the Effectiveness and Cost-effectiveness of Levetiracetam, Zonisamide, or Lamotrigine for Newly Diagnosed Focal Epilepsy: An Open-label, Non-inferiority, Multicentre, Phase 4, Randomised Controlled Trial." Lancet, vol. 397, no. 10282, 2021, p. 1363, https://doi.org/10.1016/S0140-6736(21)00247-6.